# Giant ovarian yolk sac tumor during late pregnancy: a case report and literature review

**Authors:** Qin Wang, Jianxin Zuo, Chong Liu, Huansheng Zhou, Wenjie Wang, Yankui Wang

PMC · DOI: 10.3389/fonc.2024.1437728 · 2024-09-06

## TL;DR

A rare case of a giant ovarian yolk sac tumor during late pregnancy is reported, highlighting the importance of early detection and treatment for better outcomes.

## Contribution

This case report adds to the limited literature on giant ovarian yolk sac tumors during pregnancy and emphasizes clinical management strategies.

## Key findings

- A 28-year-old pregnant woman was diagnosed with a giant ovarian yolk sac tumor at 29 weeks gestation.
- Combination surgery and chemotherapy led to a positive outcome for both mother and newborn.
- Early detection and intervention are critical for managing ovarian malignancies during pregnancy.

## Abstract

The manifestation of a giant ovarian yolk sac tumor during late pregnancy is relatively rare. A yolk sac tumor is a highly malignant germ cell tumor that originates from primitive germ cells. It is characterized by yolk sac differentiation in vitro. The frequency of prenatal examinations should be appropriately increased for ovarian tumors discovered during pregnancy. Furthermore, regular follow-up ultrasound should be performed, and tumor markers should be dynamically detected. If needed, imaging examinations such as computed tomography and magnetic resonance imaging should be combined to comprehensively investigate disease progression. If the tumor diameter and tumor marker levels rapidly increase during pregnancy, the possibility of malignancy increases. Therefore, exploratory laparotomy should be immediately performed to further improve subsequent treatment modalities, early diagnosis, early treatment, and prognosis. Herein, we report the case of a 28-year-old pregnant woman whose pregnancy was terminated at 29 weeks and 5 days. She complained of lower abdominal pain for 2 days. A pelvic mass was detected for 1 week, accompanied by increased levels of tumor markers such as serum alpha-fetoprotein, cancer antigen 125, carbohydrate antigen 724, and human epididymis protein 4. Imaging revealed the presence of a pelvic mass. At 32 weeks and 3 days of pregnancy, a cesarean section was performed, with a transverse incision in the lower uterine segment. Furthermore, pelvic adhesiolysis, omentectomy, right adnexectomy, right pelvic lymph node dissection, and pelvic metastasis peritonectomy were performed. The postoperative pathological diagnosis was yolk sac tumors of the ovary (stage IIB). Postoperatively, a five-cycle chemotherapy regimen comprising bleomycin, etoposide, and cisplatin was administered. During postoperative follow-up, the patient’s general condition was noted to be good, with the newborn and pregnant women ultimately achieving good outcomes. We reviewed the relevant literature to increase clinical doctors’ understanding of ovarian malignancy during pregnancy, guide treatment selection, and facilitate early intervention for associated diseases.

## Linked entities

- **Chemicals:** bleomycin (PubChem CID 5360373), etoposide (PubChem CID 36462), cisplatin (PubChem CID 5460033)
- **Diseases:** ovarian yolk sac tumor (MONDO:0006344)

## Full-text entities

- **Genes:** AFP (alpha fetoprotein) [NCBI Gene 174] {aka AFPD, FETA, HPAFP}
- **Diseases:** abdominal pain (MESH:D015746), yolk sac tumor (MESH:D018240), pelvic metastasis (MESH:D009362), pelvic mass (MESH:C536030), Giant ovarian yolk sac tumor (MESH:D010051), malignancy (MESH:D009369), germ cell tumor (MESH:D009373)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11412797/full.md

---
Source: https://tomesphere.com/paper/PMC11412797